Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization

Obesity Reviews

Volumn 16, Issue 10, 2015, Pages 871-882

  Sabath, E ^a   Baez Ruiz A ^a   Buijs, R M ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Obesity; Steatosis; Suprachiasmatic; Sympathetic

Indexed keywords

ADIPONECTIN; ENDOTOXIN; FATTY ACID; VERY LOW DENSITY LIPOPROTEIN; CIRCADIAN RHYTHM SIGNALING PROTEIN;

ADRENERGIC STIMULATION; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVE; AUTONOMIC NERVOUS SYSTEM; CIRCADIAN RHYTHM; DIET RESTRICTION; FAT INTAKE; FATTY ACID OXIDATION; FATTY LIVER; FEEDING; HUMAN; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LONG TERM EXPOSURE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PARASYMPATHETIC FUNCTION; PHYSIOLOGICAL PROCESS; SYMPATHETIC FUNCTION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; COMPLICATION; GENE EXPRESSION REGULATION; LIVER; METABOLISM; MOLECULAR GENETICS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; AUTONOMIC NERVOUS SYSTEM; CIRCADIAN RHYTHM; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HUMANS; LIPOLYSIS; LIVER; MOLECULAR SEQUENCE DATA; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PERIOD CIRCADIAN PROTEINS;

EID: 84941637088     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12308     Document Type: Article

References (156)

1. Kalsbeek A, Scheer FA, Perreau-Lenz S etal. Circadian disruption and SCN control of energy metabolism. FEBS Lett 2011; 585: 1412-1426.
2. Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD, Panda S. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc Natl Acad Sci U S A 2009; 106: 21453-21458.
3. Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev 2000; 14: 2950-2961.
4. Bur IM, Zouaoui S, Fontanaud P etal. The comparison between circadian oscillators in mouse liver and pituitary gland reveals different integration of feeding and light schedules. PLoS ONE 2010; 5: e15316.
5. Bray MS, Ratcliffe WF, Grenett MH, Brewer RA, Gamble KL, Young ME. Quantitative analysis of light-phase restricted feeding reveals metabolic dyssynchrony in mice. Int J Obes (Lond) 2013; 37: 843-852.
6. Salgado-Delgado RC, Saderi N, Basualdo Mdel C, Guerrero-Vargas NN, Escobar C, Buijs RM. Shift work or food intake during the rest phase promotes metabolic disruption and desynchrony of liver genes in male rats. PLoS ONE 2013; 8: e60052.
7. Arble DM, Bass J, Laposky AD, Vitaterna MH, Turek FW. Circadian timing of food intake contributes to weight gain. Obesity (Silver Spring) 2009; 17: 2100-2102.
8. Sookoian S, Castano G, Gemma C, Gianotti TF, Pirola CJ. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13: 4242-4248.
9. Sookoian S, Gemma C, Gianotti TF, Burgueno A, Castano G, Pirola CJ. Genetic variants of Clock transcription factor are associated with individual susceptibility to obesity. Am J Clin Nutr 2008; 87: 1606-1615.
10. Woon PY, Kaisaki PJ, Braganca J etal. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci U S A 2007; 104: 14412-14417.
11. Bo S, Musso G, Beccuti G etal. Consuming more of daily caloric intake at dinner predisposes to obesity. A 6-year population-based prospective cohort study. PLoS ONE 2014; 9: e108467.
12. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-1307.
13. Cuthbertson DJ, Weickert MO, Lythgoe D etal. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol 2014; 171: 561-569.
14. Chalasani N, Younossi Z, Lavine JE etal. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811-826.
15. Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: an update. World J Gastroenterol 2014; 20: 9050-9054.
16. Yilmaz Y. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome? World J Hepatol 2012; 4: 332-334.
17. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013; 48: 434-441.
18. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838.
19. Shostak A, Meyer-Kovac J, Oster H. Circadian regulation of lipid mobilization in white adipose tissues. Diabetes 2013; 62: 2195-2203.
20. Sukumaran S, Xue B, Jusko WJ, Dubois DC, Almon RR. Circadian variations in gene expression in rat abdominal adipose tissue and relationship to physiology. Physiol Genomics 2010; 42A: 141-152.
21. Frayn KN, Humphreys SM, Coppack SW. Fuel selection in white adipose tissue. Proc Nutr Soc 1995; 54: 177-189.
22. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329-339.
23. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003; 29: 478-485.
24. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
25. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351.
26. Wang S, Soni KG, Semache M etal. Lipolysis and the integrated physiology of lipid energy metabolism. Mol Genet Metab 2008; 95: 117-126.
27. Kreier F, Fliers E, Voshol PJ etal. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat - functional implications. J Clin Invest 2002; 110: 1243-1250.
28. Izumida Y, Yahagi N, Takeuchi Y etal. Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization. Nat Commun 2013; 4: 2316.
29. Kreier F, Kap YS, Mettenleiter TC etal. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology 2006; 147: 1140-1147.
30. Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula IJ, Brown NF, O'Doherty RM. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 2008; 294: E969-E977.
31. Croci I, Byrne NM, Choquette S etal. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut 2013; 62: 1625-1633.
32. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013; 58: 1497-1507.
33. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-1664.
34. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011; 14: 804-810.
35. Peek CB, Affinati AH, Ramsey KM etal. Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science 2013; 342: 1243417.
36. von Meyenn F, Porstmann T, Gasser E etal. Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism. Cell Metab 2013; 17: 436-447.
37. Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 2006; 3: 99-110.
38. Fulco M, Sartorelli V. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle 2008; 7: 3669-3679.
39. Saggerson D. Malonyl-CoA, a key signaling molecule in mammalian cells. Annu Rev Nutr 2008; 28: 253-272.
40. Fuse Y, Hirao A, Kuroda H, Otsuka M, Tahara Y, Shibata S. Differential roles of breakfast only (one meal per day) and a bigger breakfast with a small dinner (two meals per day) in mice fed a high-fat diet with regard to induced obesity and lipid metabolism. J Circadian Rhythms 2012; 10: 4.
41. Wang H, Sreenivasan U, Hu H etal. Perilipin 5, a lipid droplet-associated protein, provides physical and metabolic linkage to mitochondria. J Lipid Res 2011; 52: 2159-2168.
42. Carreno FR, Seelaender MC. Liver denervation affects hepatocyte mitochondrial fatty acid transport capacity. Cell Biochem Funct 2004; 22: 9-17.
43. Olgin JE, Sih HJ, Hanish S etal. Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation. Circulation 1998; 98: 2608-2614.
44. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006; 116: 615-622.
45. Gerhart-Hines Z, Dominy JE Jr, Blattler SM etal. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol Cell 2011; 44: 851-863.
46. Nomura T, Nomura Y, Tachibana M etal. Alpha 1-adrenergic regulation of ketogenesis in isolated rat hepatocytes. Biochim Biophys Acta 1991; 1092: 94-100.
47. Oberhaensli RD, Schwendimann R, Keller U. Effect of norepinephrine on ketogenesis, fatty acid oxidation, and esterification in isolated rat hepatocytes. Diabetes 1985; 34: 774-779.
48. Buijs RM, la Fleur SE, Wortel J etal. The suprachiasmatic nucleus balances sympathetic and parasympathetic output to peripheral organs through separate preautonomic neurons. J Comp Neurol 2003; 464: 36-48.
49. Terazono H, Mutoh T, Yamaguchi S etal. Adrenergic regulation of clock gene expression in mouse liver. Proc Natl Acad Sci U S A 2003; 100: 6795-6800.
50. Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 2011; 22: 353-363.
51. Olofsson SO, Boren J. Apolipoprotein B secretory regulation by degradation. Arterioscler Thromb Vasc Biol 2012; 32: 1334-1338.
52. Marrino P, Gavish D, Shafrir E, Eisenberg S. Diurnal variations of plasma lipids, tissue and plasma lipoprotein lipase, and VLDL secretion rates in the rat. A model for studies of VLDL metabolism. Biochim Biophys Acta 1987; 920: 277-284.
53. Mondola P, Gambardella P, Santangelo F, Santillo M, Greco AM. Circadian rhythms of lipid and apolipoprotein pattern in adult fasted rats. Physiol Behav 1995; 58: 175-180.
54. Bruinstroop E, Pei L, Ackermans MT etal. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes 2012; 61: 1043-1050.
55. Bruinstroop E, la Fleur SE, Ackermans MT etal. The autonomic nervous system regulates postprandial hepatic lipid metabolism. Am J Physiol Endocrinol Metab 2013; 304: E1089-E1096.
56. Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis 2013; 33: 380-388.
57. Cano A, Ciaffoni F, Safwat GM etal. Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver disease: is there a role for dietary coenzyme Q? J Appl Physiol (1985) 2009; 107: 707-717.
58. Pan X, Hussain MM. Clock is important for food and circadian regulation of macronutrient absorption in mice. J Lipid Res 2009; 50: 1800-1813.
59. Williams KJ. Molecular processes that handle - and mishandle - dietary lipids. J Clin Invest 2008; 118: 3247-3259.
60. Benavides A, Siches M, Llobera M. Circadian rhythms of lipoprotein lipase and hepatic lipase activities in intermediate metabolism of adult rat. Am J Physiol 1998; 275: R811-R817.
61. Klingenspor M, Ebbinghaus C, Hulshorst G etal. Multiple regulatory steps are involved in the control of lipoprotein lipase activity in brown adipose tissue. J Lipid Res 1996; 37: 1685-1695.
62. Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 2014; 1841: 919-933.
63. Ruge T, Hodson L, Cheeseman J etal. Fasted to fed trafficking of fatty acids in human adipose tissue reveals a novel regulatory step for enhanced fat storage. J Clin Endocrinol Metab 2009; 94: 1781-1788.
64. McQuaid SE, Hodson L, Neville MJ etal. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes 2011; 60: 47-55.
65. Raynolds MV, Awald PD, Gordon DF etal. Lipoprotein lipase gene expression in rat adipocytes is regulated by isoproterenol and insulin through different mechanisms. Mol Endocrinol 1990; 4: 1416-1422.
66. Teusink B, Voshol PJ, Dahlmans VE etal. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 2003; 52: 614-620.
67. Chong MF, Fielding BA, Frayn KN. Metabolic interaction of dietary sugars and plasma lipids with a focus on mechanisms and de novo lipogenesis. Proc Nutr Soc 2007; 66: 52-59.
68. Feng D, Liu T, Sun Z etal. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 2011; 331: 1315-1319.
69. Hems DA, Rath EA, Verrinder TR. Fatty acid synthesis in liver and adipose tissue of normal and genetically obese (ob/ob) mice during the 24-hour cycle. Biochem J 1975; 150: 167-173.
70. Horton JD, Bashmakov Y, Shimomura I, Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci U S A 1998; 95: 5987-5992.
71. Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr 2005; 81: 35-42.
72. Kohjima M, Higuchi N, Kato M etal. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008; 21: 507-511.
73. Mitsuyoshi H, Yasui K, Harano Y etal. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res 2009; 39: 366-373.
74. Moon YA, Liang G, Xie X etal. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 2012; 15: 240-246.
75. Shen L, Cui A, Xue Y etal. Hepatic differentiated embryo-chondrocyte-expressed gene 1 (Dec1) inhibits sterol regulatory element-binding protein-1c (Srebp-1c) expression and alleviates fatty liver phenotype. J Biol Chem 2014; 289: 23332-23342.
76. Matsumoto E, Ishihara A, Tamai S etal. Time of day and nutrients in feeding govern daily expression rhythms of the gene for sterol regulatory element-binding protein (SREBP)-1 in the mouse liver. J Biol Chem 2010; 285: 33028-33036.
77. Cretenet G, Le Clech M, Gachon F. Circadian clock-coordinated 12 Hr period rhythmic activation of the IRE1alpha pathway controls lipid metabolism in mouse liver. Cell Metab 2010; 11: 47-57.
78. Mallat A, Teixeira-Clerc F, Lotersztajn S. Cannabinoid signaling and liver therapeutics. J Hepatol 2013; 59: 891-896.
79. Osei-Hyiaman D, DePetrillo M, Pacher P etal. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
80. Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid signalling: has it got rhythm? Br J Pharmacol 2010; 160: 530-543.
81. Hanlon EC, Tasali E, Leproult R etal. Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol. J Clin Endocrinol Metab 2015; 100: 220-226.
82. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148: 852-871.
83. Flannery C, Dufour S, Rabol R, Shulman GI, Petersen KF. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 2012; 61: 2711-2717.
84. Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr 2010; 30: 273-290.
85. Rabol R, Petersen KF, Dufour S, Flannery C, Shulman GI. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A 2011; 108: 13705-13709.
86. Leighton B, Kowalchuk JM, Challiss RA, Newsholme EA. Circadian rhythm in sensitivity of glucose metabolism to insulin in rat soleus muscle. Am J Physiol 1988; 255: E41-E45.
87. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev 1997; 18: 716-738.
88. Mazzoccoli G, Vinciguerra M, Oben J, Tarquini R, De Cosmo S. Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. Liver Int 2014; 34: 1133-1152.
89. Salgado-Delgado R, Angeles-Castellanos M, Saderi N, Buijs RM, Escobar C. Food intake during the normal activity phase prevents obesity and circadian desynchrony in a rat model of night work. Endocrinology 2010; 151: 1019-1029.
90. Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown WJ, Brown DA. Adipocyte differentiation-related protein reduces the lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover. J Lipid Res 2007; 48: 2751-2761.
91. Chang BH, Chan L. Regulation of triglyceride metabolism. III. Emerging role of lipid droplet protein ADFP in health and disease. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1465-G1468.
92. Chang BH, Li L, Paul A etal. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol 2006; 26: 1063-1076.
93. Motomura W, Inoue M, Ohtake T etal. Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem Biophys Res Commun 2006; 340: 1111-1118.
94. Birketvedt GS, Florholmen J, Sundsfjord J etal. Behavioral and neuroendocrine characteristics of the night-eating syndrome. JAMA 1999; 282: 657-663.
95. Wang JC, Gray NE, Kuo T, Harris CA. Regulation of triglyceride metabolism by glucocorticoid receptor. Cell Biosci 2012; 2: 19.
96. Manmontri B, Sariahmetoglu M, Donkor J etal. Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically. J Lipid Res 2008; 49: 1056-1067.
97. Letteron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol 1997; 272: G1141-G1150.
98. Harris C, Roohk DJ, Fitch M, Boudignon BM, Halloran BP, Hellerstein MK. Large increases in adipose triacylglycerol flux in Cushingoid CRH-Tg mice are explained by futile cycling. Am J Physiol Endocrinol Metab 2013; 304: E282-E293.
99. Bell ME, Bhargava A, Soriano L, Laugero K, Akana SF, Dallman MF. Sucrose intake and corticosterone interact with cold to modulate ingestive behaviour, energy balance, autonomic outflow and neuroendocrine responses during chronic stress. J Neuroendocrinol 2002; 14: 330-342.
100. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
101. Wong VW, Wong GL, Choi PC etal. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.
102. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330.
103. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 2013; 1281: 106-122.
104. Day CP, James OF. Steatohepatitis: a tale of two 'hits. Gastroenterology 1998; 114: 842-845.
105. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.
106. Carter R, Mouralidarane A, Soeda J etal. Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms. PLoS ONE 2014; 9: e89505.
107. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10: 627-636.
108. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012; 6: 149-171.
109. Compare D, Coccoli P, Rocco A etal. Gut - liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22: 471-476.
110. Verdam FJ, Rensen SS, Driessen A, Greve JW, Buurman WA. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol 2011; 45: 149-152.
111. Miele L, Valenza V, La Torre G etal. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
112. Costantini TW, Bansal V, Krzyzaniak M etal. Vagal nerve stimulation protects against burn-induced intestinal injury through activation of enteric glia cells. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1308-G1318.
113. Schaper J, Wagner A, Enigk F etal. Regional sympathetic blockade attenuates activation of intestinal macrophages and reduces gut barrier failure. Anesthesiology 2013; 118: 134-142.
114. Guerrero-Vargas NN, Salgado-Delgado R, Basualdo Mdel C etal. Reciprocal interaction between the suprachiasmatic nucleus and the immune system tunes down the inflammatory response to lipopolysaccharide. J Neuroimmunol 2014; 273: 22-30.
115. Castanon-Cervantes O, Wu M, Ehlen JC etal. Dysregulation of inflammatory responses by chronic circadian disruption. J Immunol 2010; 185: 5796-5805.
116. Leproult R, Holmback U, Van Cauter E. Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss. Diabetes 2014; 63: 1860-1869.
117. Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004; 40: 19-22.
118. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19: 802-812.
119. Fukushima J, Kamada Y, Matsumoto H etal. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 2009; 39: 724-738.
120. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 2005; 39: 237-242.
121. Musso G, Gambino R, Durazzo M etal. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175-1183.
122. Scheer FA, Chan JL, Fargnoli J etal. Day/night variations of high-molecular-weight adiponectin and lipocalin-2 in healthy men studied under fed and fasted conditions. Diabetologia 2010; 53: 2401-2405.
123. Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 2002; 367: 677-685.
124. Iwen KA, Wenzel ET, Ott V etal. Cold-induced alteration of adipokine profile in humans. Metabolism 2011; 60: 430-437.
125. Suzuki Y, Shimizu H, Ishizuka N etal. Vagal hyperactivity due to ventromedial hypothalamic lesions increases adiponectin production and release. Diabetes 2014; 63: 1637-1648.
126. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725.e716.
127. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 2011; 32: 234-246.
128. Wilking M, Ndiaye M, Mukhtar H, Ahmad N. Circadian rhythm connections to oxidative stress: implications for human health. Antioxid Redox Signal 2013; 19: 192-208.
129. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008; 60: 311-357.
130. Hardeland R, Coto-Montes A, Poeggeler B. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol Int 2003; 20: 921-962.
131. Xu YQ, Zhang D, Jin T etal. Diurnal variation of hepatic antioxidant gene expression in mice. PLoS ONE 2012; 7: e44237.
132. Bruckner JV, Ramanathan R, Lee KM, Muralidhara S. Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther 2002; 300: 273-281.
133. Pekovic-Vaughan V, Gibbs J, Yoshitane H etal. The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. Genes Dev 2014; 28: 548-560.
134. Vecoli C, Paolocci N. When the heart sleeps... is the vagus resetting the myocardial 'redox clock'? Cardiovasc Res 2008; 77: 609-611.
135. Andersson DC, Fauconnier J, Yamada T etal. Mitochondrial production of reactive oxygen species contributes to the beta-adrenergic stimulation of mouse cardiomycytes. J Physiol 2011; 589: 1791-1801.
136. Tsutsumi T, Ide T, Yamato M etal. Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction. Cardiovasc Res 2008; 77: 713-721.
137. Schultz HD, Ustinova EE. Capsaicin receptors mediate free radical-induced activation of cardiac afferent endings. Cardiovasc Res 1998; 38: 348-355.
138. Taylor-Clark TE, Undem BJ. Sensing pulmonary oxidative stress by lung vagal afferents. Respir Physiol Neurobiol 2011; 178: 406-413.
139. Rhee SG, Woo HA, Kil IS, Bae SH. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem 2012; 287: 4403-4410.
140. Edgar RS, Green EW, Zhao Y etal. Peroxiredoxins are conserved markers of circadian rhythms. Nature 2012; 485: 459-464.
141. Hoyle NP, O'Neill JS. Oxidation-reduction cycles of peroxiredoxin proteins and nontranscriptional aspects of timekeeping. Biochemistry 2015; 54: 184-193.
142. Lee J, Moulik M, Fang Z etal. Bmal1 and beta-cell clock are required for adaptation to circadian disruption, and their loss of function leads to oxidative stress-induced beta-cell failure in mice. Mol Cell Biol 2013; 33: 2327-2338.
143. Pacifici F, Arriga R, Sorice GP etal. Peroxiredoxin 6, a novel player in the pathogenesis of diabetes. Diabetes 2014; 63: 3210-3220.
144. Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol 2013; 19: 6735-6743.
145. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000; 917: 376-386.
146. Chung MH, Kuo TB, Hsu N, Chu H, Chou KR, Yang CC. Sleep and autonomic nervous system changes - enhanced cardiac sympathetic modulations during sleep in permanent night shift nurses. Scand J Work Environ Health 2009; 35: 180-187.
147. Wehrens SM, Hampton SM, Skene DJ. Heart rate variability and endothelial function after sleep deprivation and recovery sleep among male shift and non-shift workers. Scand J Work Environ Health 2012; 38: 171-181.
148. Dauphinot V, Gosse P, Kossovsky MP etal. Autonomic nervous system activity is independently associated with the risk of shift in the non-dipper blood pressure pattern. Hypertens Res 2010; 33: 1032-1037.
149. Weyer C, Salbe AD, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans? Metabolism 2001; 50: 223-230.
150. Jin R, Le NA, Liu S etal. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab 2012; 97: E1088-E1098.
151. Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res 2009; 19: 319-326.
152. Oliver MI, Miralles R, Rubies-Prat J etal. Autonomic dysfunction in patients with non-alcoholic chronic liver disease. J Hepatol 1997; 26: 1242-1248.
153. Sun W, Zhang D, Sun J etal. Association between non-alcoholic fatty liver disease and autonomic dysfunction in a Chinese population. QJM 2015; pii: hcv006. [Epub ahead of print].
154. Gonciarz M, Gonciarz Z, Bielanski W etal. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012; 63: 35-40.
155. Hatzis G, Ziakas P, Kavantzas N etal. Melatonin attenuates high fat diet-induced fatty liver disease in rats. World J Hepatol 2013; 5: 160-169.
156. Jakovljevic DG, Hallsworth K, Zalewski P etal. Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease. Clin Sci (Lond) 2013; 125: 143-149.